基于MRI的肿瘤内异质性定量预测接受放疗的肺癌脑转移患者无进展生存期
回顾性分析68例肺癌脑转移患者的146个病灶,从全肿瘤和肿瘤亚区提取常规影像组学与栖息地特征,构建临床、影像组学、栖息地及联合风险模型预测无进展生存期。栖息地风险模型在时间独立测试队列中预测能力最佳(C-Index 0.716;95% CI 0.548-0.890),栖息地和影像组学模型在训练及时间独立测试队列中均优于临床模型。
要点
- 栖息地风险模型在时间独立测试队列中C-Index为0.716(95% CI 0.548-0.890),为4种模型中最佳。
- 栖息地和影像组学模型在训练队列(C-Index 0.721-0.762 vs 0.697)及时间独立测试队列(0.630-0.716 vs 0.377)中均优于临床模型。
- 基于肿瘤内异质性的栖息地特征可能成为预测放疗后无进展生存期的可靠生物标志物。
核心结论
- 基于肿瘤内异质性的栖息地风险模型可能成为预测接受放疗的肺癌脑转移患者无进展生存期的可靠生物标志物。
研究设计与样本
- 回顾性研究,纳入68例肺癌脑转移患者的146个病灶,分为训练、随机测试和时间独立测试队列;从全肿瘤区域和肿瘤亚区分别提取常规影像组学和栖息地特征,构建临床、影像组学、栖息地及临床+栖息地联合风险模型,以C-Index和Brier评分评估,Kaplan-Meier曲线评估预后价值。
诊断标准与关键数值
- 栖息地风险模型在时间独立测试队列中C-Index为0.716(95% CI 0.548-0.890),为4种风险模型中预测能力最佳。
- 栖息地和影像组学风险模型在训练队列中C-Index为0.721-0.762,临床风险模型为0.697。
- 栖息地和影像组学风险模型在时间独立测试队列中C-Index为0.630-0.716,临床风险模型为0.377。
临床应用与阅片要点
- 作者认为基于肿瘤内异质性的栖息地风险模型可能成为预测接受放疗的肺癌脑转移患者无进展生存期的可靠生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Our aim was to investigate the potential of using MRI-based habitat features for predicting progression-free survival (PFS) in patients with lung cancer brain metastasis (LCBM) receiving radiotherapy.
MATERIALS AND METHODS: One hundred and forty-six lesions from 68 patients with LCBM receiving radiotherapy were retrospectively reviewed and divided into training, random test (R-test), and time-independent test (TI-test) cohorts. Conventional radiomics and habitat features were extracted from the whole-tumor area and tumor subregions, respectively. Different machine learning risk models for predicting PFS were developed on the basis of clinical, radiomics, and habitat features, and their combination (clinical + habitat), respectively. The performance of the risk models was evaluated using the concordance index (C-Index) and Brier scores. The Kaplan-Meier curve was used to assess the prognostic value of the models.
RESULTS: The habitat risk model achieved the best prediction ability among 4 different risk models in the TI-test cohort (C-Index: 0.716; 95% CI, 0.548-0.890). Additionally, the habitat and radiomics risk models outperformed the clinical risk model in the training (C-Index: 0.721-0.762 versus 0.697) and TI-test cohorts (C-Index: 0.630-0.716 versus 0.377).
CONCLUSIONS: A habitat risk model based on intratumoral heterogeneity could be a reliable biomarker for predicting PFS in patients with LCBM receiving radiotherapy.
引用
- Guo W, Lin L, Wu Y, et al. MRI-Based Quantification of Intratumoral Heterogeneity for Predicting Progression-Free Survival in Patients with Lung Cancer Brain Metastasis Receiving Radiotherapy. AJNR Am J Neuroradiol. 2025. PMID: 41102007. doi:10.3174/ajnr.A8869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。